Poor adherence to population-based vaccination in two counties after meningococcal B:14:P1.7,16 outbreak: an illustration of the growing vaccine hesitancy in France.


Journal

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
ISSN: 1769-664X
Titre abrégé: Arch Pediatr
Pays: France
ID NLM: 9421356

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 25 07 2018
revised: 05 11 2018
accepted: 11 12 2018
pubmed: 9 1 2019
medline: 21 3 2019
entrez: 9 1 2019
Statut: ppublish

Résumé

Neisseria meningitidis is a virulent bacteria provoking outbreaks of invasive meningococcal disease (IMD) that authorities may try to control with population-based vaccinations. Such campaigns are most often thoroughly followed. We assess the response of poor adherence during a population-based vaccination after a meningococcal B:14:P1.7,16 outbreak. Between July, 2012, and April, 2013, six cases including one fatality of invasive meningococcal disease related to N. meningitidis B:14:P1.7,16/ST32 were reported in two neighboring counties. A vaccination campaign with MenBVac The number of immunized patients proved to be low, with 1721 (24.1%) receiving at least one dose out of 5069 doses administered. However, the incidence of IMD in the zone dramatically fell, with only one purpura fulminans case in June 2014 with a good outcome. The campaign was stopped after 1 year and a 2-year monitoring period was implemented until June, 2016, with no new cases. This outbreak probably self-terminated in a context of a low incidence of serogroup B IMD during 2014 in France. Poor adherence illustrates the growing vaccine hesitancy in France. Similar campaigns will have to be thoroughly planned and implemented in terms of timing, modalities of injections, and mass communication.

Sections du résumé

BACKGROUND BACKGROUND
Neisseria meningitidis is a virulent bacteria provoking outbreaks of invasive meningococcal disease (IMD) that authorities may try to control with population-based vaccinations. Such campaigns are most often thoroughly followed. We assess the response of poor adherence during a population-based vaccination after a meningococcal B:14:P1.7,16 outbreak.
METHODS METHODS
Between July, 2012, and April, 2013, six cases including one fatality of invasive meningococcal disease related to N. meningitidis B:14:P1.7,16/ST32 were reported in two neighboring counties. A vaccination campaign with MenBVac
RESULTS RESULTS
The number of immunized patients proved to be low, with 1721 (24.1%) receiving at least one dose out of 5069 doses administered. However, the incidence of IMD in the zone dramatically fell, with only one purpura fulminans case in June 2014 with a good outcome. The campaign was stopped after 1 year and a 2-year monitoring period was implemented until June, 2016, with no new cases.
CONCLUSIONS CONCLUSIONS
This outbreak probably self-terminated in a context of a low incidence of serogroup B IMD during 2014 in France. Poor adherence illustrates the growing vaccine hesitancy in France. Similar campaigns will have to be thoroughly planned and implemented in terms of timing, modalities of injections, and mass communication.

Identifiants

pubmed: 30617005
pii: S0929-693X(18)30268-9
doi: 10.1016/j.arcped.2018.12.004
pii:
doi:

Substances chimiques

Meningococcal Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

75-79

Informations de copyright

Copyright © 2018. Published by Elsevier Masson SAS.

Auteurs

S Cabasson (S)

Service de pédiatrie et réanimation pédiatrique, Centre hospitalier de Pau, Boulevard Hauterive, 64046 Pau, France. Electronic address: sebastiencabasson@yahoo.fr.

J Roux (J)

Service de pédiatrie et réanimation pédiatrique, Centre hospitalier de Pau, Boulevard Hauterive, 64046 Pau, France.

M Charron (M)

Cellule D'Intervention en Région (CIRE), Santé publique France, 103, rue de Belleville, 33000 Bordeaux, France.

J Sarlangue (J)

Département de pédiatrie médicale, Hôpital Pellegrin-Enfants, CHU de Bordeaux, Place Amélie-Raba-Léon, 33076 Bordeaux France.

S Debeugny (S)

Unité de recherche clinique, Centre hospitalier de Pau, Boulevard Hauterive, 64046 Pau, France.

V Jouhet (V)

Institut de Santé publique et du développement, Université Victor-Ségalen Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France.

E Monlun (E)

Service de maladies infectieuses, Centre hospitalier de Pau, Boulevard Hauterive, 64046 Pau, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH